Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia
- 1 May 2018
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 4 (5), 712-716
- https://doi.org/10.1001/jamaoncol.2017.5604
Abstract
IMPORTANCE Ibrutinib, a first-in-class Bruton tyrosine kinase inhibitor taken once daily, is approved in the United States for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and allows for treatment without chemotherapy. Extended treatment with ibrutinib has demonstrated increased complete response (CR) rates over time. OBJECTIVE To analyze baseline factors that predict CR in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma treated with ibrutinib. DESIGN, SETTING, AND PARTICIPANTS Univariate and multivariate analyses of pooled data from 2 clinical trials were used to assess the prognostic value of baseline factors associated with CR in 327 patients from the PCYC-1102 and PCYC-1112 studies treated with single-agent ibrutinib. Participants were followed up in academic and community medical centers in the United States, the United Kingdom, Australia, France, Italy, Ireland, Poland, Spain, and Austria. MAIN OUTCOMES AND MEASURES Odds ratio (OR) of CR rate. RESULTS The 327 patients included in this analysis had a median age of 67 years (range, 30-86 years) and 227 (69.4%) were male. At baseline, 185 patients (56.6%) had bulky disease (lymph node >5 cm), 184 (56.3%) had advanced-stage disease, and 182 (55.7%) had an Eastern Cooperative Oncology Group performance status of 1 or higher. Thirty-one patients (9.5%) were in the first-line setting; 38 (11.6%) had undergone 1 previous therapy, 81 (24.8%) had undergone 2, and 177 (54.1%) had undergone 3 or more; patients with relapsed/refractory disease had undergone a median of 3 (range, 0-12) previous therapies. Median time on study was 26.4 months (range, 0.3-55.6 months). Thirty-two of the 327 patients (9.8%) treated with ibrutinib had a CR (PCYC-1102: relapsed/refractory, 12 of 101 [11.9%]; treatment-naive, 8 of 31 [25.8%]; and PCYC-1112: 12 of 195 [6.2%]). The median time to CR for these patients was 14.7 months (range, 4.6-47.1 months). Univariate analysis of baseline factors showed that bulky disease, clinical stage, number of previous therapies, and beta 2-microglobulin concentration had a significant effect on the odds of CR. The final multivariate model showed that patients with no previous therapy vs patients with at least 1 previous therapy (OR, 2.65; 95% CI, 1.01-6.95; P = .047) and patients without bulky disease (lymph node = 5 cm[OR, 4.97; 95% CI, 1.91-12.91; P =.001]) had an increased likelihood of CR. CONCLUSIONS AND RELEVANCE Patients receiving ibrutinib as a first-line therapy for chronic lymphocytic leukemia and those without bulky disease had a better likelihood of CR to treatment. The CR rate with continued longer-term ibrutinib treatment was higher than in previous reports.Keywords
This publication has 12 references indexed in Scilit:
- Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLLBlood, 2016
- The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemiaBlood, 2015
- Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinibBlood, 2015
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid LeukemiaNew England Journal of Medicine, 2014
- The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapyHaematologica, 2014
- Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trialThe Lancet Oncology, 2013
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2013
- Chronic lymphocytic leukemiaAnnals Of Oncology, 2010
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelinesBlood, 2008
- Toxicity and response criteria of the Eastern Cooperative Oncology GroupAmerican Journal of Clinical Oncology, 1982